Shots:
- PTC Therapeutics has been selected as the winning bidder to acquire ST-920, a BLA-stage, one-time AAV gene therapy for Fabry disease, from Sangamo Therapeutics through a competitive bankruptcy auction
- As per the terms, PTC Therapeutics will pay $111M upfront, with up to $100M in contingent milestone payments tied to certain regulatory approvals; expected to close in Q3’26 or early Q4’26
- A rolling BLA submission for accelerated approval of ST-920 is expected to be completed in Q4’26, supported by 52wk. P-I/II (STAAR) trial data showing meaningful renal function benefits, with potential launch expected in 2027
Ref: PRnewswire | Image: PTC Therapeutics | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
